Zacks Investment Research upgraded shares of Albireo Pharma (NASDAQ:ALBO) from a sell rating to a hold rating in a report released on Friday.
According to Zacks, “Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. “
Several other equities analysts have also recently issued reports on the company. Wedbush reaffirmed an outperform rating and issued a $63.00 price objective on shares of Albireo Pharma in a research report on Wednesday. BidaskClub cut Albireo Pharma from a buy rating to a hold rating in a research report on Wednesday. Needham & Company LLC assumed coverage on Albireo Pharma in a research report on Thursday, March 15th. They issued a buy rating and a $50.00 price objective on the stock. Finally, ValuEngine raised Albireo Pharma from a sell rating to a hold rating in a research report on Friday, February 2nd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $59.50.
Albireo Pharma (NASDAQ:ALBO) last released its quarterly earnings data on Thursday, March 15th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.23. equities analysts anticipate that Albireo Pharma will post 0.77 earnings per share for the current fiscal year.
In other news, major shareholder Life Sciences Maste Perceptive purchased 275,000 shares of the stock in a transaction dated Thursday, January 25th. The shares were purchased at an average cost of $33.00 per share, with a total value of $9,075,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Phase4 Partners Ltd sold 100,000 shares of the stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $34.44, for a total value of $3,444,000.00. The disclosure for this sale can be found here. Corporate insiders own 22.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALBO. Perceptive Advisors LLC lifted its holdings in shares of Albireo Pharma by 56.2% during the 4th quarter. Perceptive Advisors LLC now owns 1,320,000 shares of the biopharmaceutical company’s stock valued at $33,792,000 after buying an additional 475,000 shares during the period. Artal Group S.A. bought a new position in shares of Albireo Pharma during the 4th quarter valued at $7,680,000. Sectoral Asset Management Inc lifted its holdings in shares of Albireo Pharma by 53.6% during the 4th quarter. Sectoral Asset Management Inc now owns 242,803 shares of the biopharmaceutical company’s stock valued at $6,216,000 after buying an additional 84,776 shares during the period. Millennium Management LLC lifted its holdings in shares of Albireo Pharma by 65.4% during the 4th quarter. Millennium Management LLC now owns 46,594 shares of the biopharmaceutical company’s stock valued at $1,193,000 after buying an additional 18,425 shares during the period. Finally, Ardsley Advisory Partners bought a new position in shares of Albireo Pharma during the 4th quarter valued at $289,000. 29.43% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was originally posted by WKRB News and is the property of of WKRB News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.wkrb13.com/2018/03/31/albireo-pharma-albo-upgraded-at-zacks-investment-research.html.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.